The tech solution provides construction customers with an automated layout-as-a-service tool. Image via rugged-robotics.com

A Houston robotics startup working in the commercial construction field has closed its latest round of funding.

Rugged Robotics Inc. announced last week that it's raised $9.4 million in its series A round led by BOLD Capital Partners and Brick & Mortar Ventures. Riot Ventures, Morpheus, and Embark — all investors in the company's 2019 seed round — also contributed, as did Consigli Construction Company and Suffolk Technologies. To date, Rugged Robotics has raised $12 million.

“We are thrilled to be part of the Rugged team,” says Maxx Bricklin, partner at BOLD Capital, in a news release. “We looked at a number of companies in the space and became convinced that the Rugged team, technology and partner ecosystem would allow Rugged to dominate and capitalize on this significant and disruptive market opportunity.”

The fresh capital, the company shares in the release, will go toward scaling operations, expanding offerings, and continuing research and development.

Founded in 2018 by construction industry veteran Derrick Morse and former NASA engineer Logan Farrell, Rugged Robotics's Mark 1 product is modernizing the construction industry. The robot addresses challenges of field layout with a “layout Roomba” that marks architectural and engineering designs directly onto unfinished concrete floors. The company's early customers include Consigli Construction Co, Suffolk Construction, and Brasfield & Gorrie.

“When Derrick and Logan first visited our office, they clearly understood the problems we face and immediately separated themselves from typical technology startups. Their focus on solving real-world problems resonates with us, and we jumped at the opportunity to engage with them,” says Mike Haseltine, vice president and head of operations at Consigli. “Seeing their robots, their layouts, and their impact is inspiring. They’ve built something that’s going to change how we build buildings.”

While the concept of an autonomous layout solution isn't new, the Rugged Robotics approach is different from the industry standard in that it has a self-contained system that "enables multi-rover deployments, one-time set-ups that span an entire floor, and print zones that extend around and behind obstructions like columns, stairs, and elevators," per the news release. The company offers its customers the technology as a layout-as-a-service model.

“We’re building better,” says Morse, who serves as CEO, in the release. “We set out to modernize the construction industry, and to build practical solutions that solve the pain points contractors struggle with every day. We believe that layout is the ideal starting point. Layout is the beachhead for construction automation. It sits at the intersection of the digital and physical world, solves a huge problem, and unlocks the ability to deploy robotics onto job sites in a very meaningful way.”

The company is growing its team, which has included the onboarding of Mason Markee, the former director of mechanical engineering of Auris Health, who joined Rugged Robotics as vice president of engineering. Prior to Auris, Markee spent eight years at NASA as a robotics engineer.

“Mason has 15 years of years of robotics experience," says Farrell, the company's CTO, in the release. "I knew him at NASA, and we’re delighted to have him onboard at Rugged. He brings tremendous experience to the table. He is familiar with the entire product life cycle, from concept generation to final commercial production. He’s seen scale, and we’re excited by the rapid growth his technical expertise and leadership experience enables.”

The company has five engineering positions listed on LinkedIn.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.